ClavystBio
VC Fund
Singapore, Singapore
ClavystBio is a VC fund in Singapore focused on Biotechnology and Health Care. ClavystBio invest in early-stage ventures in the biotech, medTech, and digital health sectors, as well as in real estate and services.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 53%
Last updated:
For AI agents: llms.txt
Industries ClavystBio invests in
Stages ClavystBio invests in
Countries ClavystBio invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $12M–$187M
- Venture - Series Unknown
- $14M–$25M
Investment Focus
Industry
- Biotechnology 11 (65%)
- Health Care 10 (59%)
- Medical 5 (29%)
- Therapeutics 4 (24%)
- Medical Device 3 (18%)
Stage
- Series A 5 (29%)
- Venture - Series Unknown 3 (18%)
- Seed 2 (12%)
- Series B 2 (12%)
- Series D 2 (12%)
Country
- Singapore 7 (41%)
- United States 6 (35%)
- The Netherlands 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Sang Shin
Director, Digital Health
|
Director, Digital Health | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Zenflow was founded in 2014 by a team of Stanford University Biodesign Fellows working in collaboration with top global urologists. After witnessing patients' frustration with existing treatment options, the founders made it their mission to find a better solution to this large unmet clinical need. | $52M / Series D / Oct 05, 2026 | ||
| They offer platforms that are able to report clinical deterioration and provide recommended interventions with post-monitoring.They work in the health care industry, just like you. We take the time to get to know you, and we always keep your best interests in mind when adding and adjusting products in our catalog. | Series A / Sep 21, 2026 | ||
| Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. | $45.4M / Jun 25, 2026 | ||
| Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $25M / Venture - Series Unknown / Jun 16, 2026 | ||
| Biobot Surgical is a global technology provider in minimally-invasive robotic healthcare solutions. | $7.8M / Series C / Apr 09, 2026 | ||
| Cirrus Therapeutics is a Biotechnology Research firm diganosing and treating eye diseases affecting ocular immune system. | $11M / Seed / Aug 19, 2025 | ||
| They offer platforms that are able to report clinical deterioration and provide recommended interventions with post-monitoring.They work in the health care industry, just like you. We take the time to get to know you, and we always keep your best interests in mind when adding and adjusting products in our catalog. | $11.6M / Series A / Jul 23, 2025 | ||
| Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $57.5M / Series D / Jun 05, 2025 | ||
| Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts. | $45M / Series B / May 06, 2025 | ||
| Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits. | $187M / Series A / Mar 03, 2025 | ||
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does ClavystBio invest in?
ClavystBio invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Venture - Series Unknown stage. Most of the 17 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does ClavystBio invest in?
ClavystBio typically joins rounds of $12M–$187M at Series A and $14M–$25M at Venture - Series Unknown. These are whole funding-round sizes, not ClavystBio's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds ClavystBio took part in.
How do I contact ClavystBio?
Public channels for ClavystBio include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ClavystBio?
The team at ClavystBio includes Sang Shin (Director, Digital Health). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
